Headquartered in Massachusetts, US,  the company has been privately owned by Pamplona Capital Management since 2017. It partners with drug manufacturers and medical device companies throughout the product development and commercialisation process.

Parexel supports the development of innovative new medicines to improve the health of patients. The company provide services to help life sciences and biopharmaceutical clients from decentralized clinical trials to regulatory consulting services to leveraging real world insights.“From at-home care options to decentralized clinical trial services to direct-to-patient shipments of drug products, we are making trials more accessible to more patients in ways that work best for them,” explains Jamie Macdonald, CEO, Parexel International Corporation.

Parexel is focused on the development of innovative new therapies to improve the world’s health. By providing a suite of groundbreaking biopharmaceutical development services the company help customers across the globe transform scientific discoveries into new treatments for patients. From clinical trial design to regulatory and consulting services to commercial and market access, their therapeutic, technical, and functional ability is underpinned by a deep convictiono. “We deliver DCTs with patients at the heart of our approach. Our fully virtual and hybrid DCTs (inclusive of home nursing) demonstrate the Parexel Promise – our commitment to treating patients and caregivers as an essential part of our team of clinical research organization experts,” adds McDonald.

Parexel’s Clinical Research Services are driven by the Parexel Promise. Which is more than just a promise, it’s a commitment to keep patients and their insights at the heart of everything they do. So, the clients feel like they’re one of Parexel’s team of experts. What makes this possible is the company’s Patient Innovation Center that works to reduce barriers to patient participation for more engagement, higher recruitment and retention, better data, and reduced timelines.

Whatever the size or scope of a client’s study is, Parexel provides the comprehensive clinical development services required, from First-in-Human through Phase IV and post-marketing follow-through. The company also have the regulatory expertise, clinical trial operations management, payer and market access planning, medical education and communications capabilities to see their customer journey through efficiently and effectively.

The company’s clinical trial supplies and logistics team put their hearts into making sure the right supplies get to the right people at the right time. No matter the complexities or locational challenges, Parexel’s team solve logistical challenges before they become a problem. As they operate globally,  the team have a deep understanding of the specifics of operating between countries – navigating everything from customs to local delivery. This end-to-end clinical logistics management makes use of industry-leading supply chain tools to find every opportunity for a more efficient, compliant clinical trial.

The company initially focused on supporting German and Japanese pharmaceutical firms, but has expanded and now has clients in more than 100 countries worldwide.Parexel partnered with data-focused marketing technology company Datavant earlier in September this year. The aim of the partnership is to enhance its clinical study design and capacity by allowing the linking of healthcare data from different sources.“We’re proud of our 18,000 colleagues worldwide whose passion and commitment have made these efforts possible and have made a difference for patients every day. Our performance in the ISR survey is an important validation of their work and Parexel’s ability to differentiate and deliver on our Patients-First focus.”

Another achievement of the company is that Parexel was named “Best Contract Research Organization” in December 2020 by an independent panel for Informa Pharma Intelligence. “This award belongs to our exceptionally talented staff—the people working tirelessly to deliver critical insights for our customers and improve patient outcomes,” said Macdonald. “We are honored to be recognized as the industry’s Best CRO by Scrip and even more pleased to see our industry—in the face of a global pandemic—take this opportunity to accelerate the adoption of a real-world, data-driven approach to clinical trial design to bring new therapies to patients sooner,” he concludes.

“From at-home care options to decentralized clinical trial services to direct-to-patient shipments of drug products, we are making trials more accessible to more patients in ways that work best for them”

Jamie Macdonald
Management
CEO
Website
parexel.com